UNSPSC 51271901: Butamben

This classification denotes an anesthetic agent with the molecular formula C11H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EFW857872Q, chemically known as p-aminobenzoic acid, butyl ester but generally known as butamben, which bears US NIH Compound Identifier 2482. Butamben most often comes in base and picrate forms. European Medicines Agency schedules Butamben in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13138MIG.

As of Q4 2014, BUTAMBEN remains the US FDA Preferred Term for this commodity. Butamben bears US NLM identifiers UMLS ID C0054235 and NCI Concept Code C75086. SMILES: CCCCOC(=O)C1=CC=C(C=C1)N.

UNSPSC 51271901 Butamben is a Commodity code for a local anesthetic product that state and local governments procure as part of broader pharmaceutical and over-the-counter (OTC) product frameworks. The code captures individual active pharmaceutical ingredients and finished-goods products distributed through state and local health systems, correctional facilities, and other government-operated medical settings. Recent solicitation activity shows that state and local buyers acquire butamben and similar pharmaceuticals via cooperative purchasing agreements that bundle multiple generic and branded products into single contracts, reducing administrative overhead and leveraging volume across jurisdictions. The issuing bodies include state departments of administration and multistate cooperative purchasing alliances that aggregate demand across participating state agencies, counties, municipalities, and subordinate health facilities.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon. Vendors must supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC), maintain contractual relationships with at least two of the three, and meet FDA compliance, cGMP certification, and Drug Supply Chain Security Act requirements. The contract term is two years for new responders with optional extensions, effective July 1, 2026, with evaluation weighted heavily on price competitiveness (75 percent), followed by fixed pricing, EDI capability, administrative fee compliance, and data format adherence. No specific award value or set-aside designations were disclosed in the solicitation materials.